List of Amyvid drug patents

Amyvid is owned by Avid Radiopharms Inc.

Amyvid contains Florbetapir F-18.

Amyvid has a total of 2 drug patents out of which 0 drug patents have expired.

Amyvid was authorised for market use on 06 April, 2012.

Amyvid is available in solution;intravenous dosage forms.

Amyvid can be used as amyvid is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment.

The generics of Amyvid are possible to be released after 30 April, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7687052 AVID RADIOPHARMS INC Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Apr, 2027

(4 years from now)

US8506929 AVID RADIOPHARMS INC Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Apr, 2027

(4 years from now)

Drugs and Companies using FLORBETAPIR F-18 ingredient

Market Authorisation Date: 06 April, 2012

Treatment: Amyvid is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in